Valneva Updates on Chikungunya Vaccine Recommendation in the U.S.
BRIEF
on VALNEVA (EPA:VLA)
Valneva SE has announced an update regarding its chikungunya vaccine, IXCHIQ®, after a meeting held by the CDC's Advisory Committee on Immunization Practices (ACIP) on April 16. IXCHIQ® remains recommended for adults aged 18 and above traveling to areas experiencing chikungunya outbreaks. It is also considered for those traveling to regions with a higher risk of the virus if the trip is extended.
However, ACIP has advised caution for vaccine use in individuals aged 65+, following reports of serious adverse events in this demographic. This caution has prompted ongoing investigations, even though no direct causal link has been established between the vaccine and these events.
Despite this, IXCHIQ® is still endorsed in pressing situations, such as outbreaks affecting this age group with comorbid conditions. Valneva has currently distributed 80,000 doses globally, with no additional adverse events reported since January 2025.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
